Trabeculectomy with intraoperative sponge 5-fluorouracil in Afro-Caribbeans

Yves Lachkar, Martin Leyland, Philip Bloom, Clive Migdal

Abstract

**Aim**—To study the efficacy and safety of intraoperative 5-fluorouracil (5-FU) in Afro-Caribbean patients.

**Methods**—The results of trabeculectomy in 18 eyes of 18 Afro-Caribbean patients in whom a sponge soaked in 25 mg/ml solution of 5-FU was applied between Tenon’s capsule and sclera for 5 minutes before excision of the trabecula were compared with 16 eyes of 16 Afro-Caribbean patients matched for age, quantity, and duration of preoperative medications, who underwent trabeculectomy without 5-FU.

**Results**—The mean postoperative intraocular pressure (IOP) at 1 month was 15.6 (SD 6.1) mm Hg in the 5-FU group and 18.0 (5.2) mm Hg in the control group (p=0.15). There was no significant difference in the IOP at 6, 12, 15, 18, and 24 months in the two groups. Success rate at 18 months defined as an IOP less than or equal to 21 mm Hg with no adjunctive medication was 56% in the 5-FU group and 55% in the control group. No major complications were noted in either group.

**Conclusion**—Intraoperative sponge 5-FU alone is safe but does not appear to decrease the risk of failure of trabeculectomy in Afro-Caribbeans.

Previous studies have reported poor success rates after routine filtration operations in Afro-Caribbean patients particularly if they are young.1–5

The use of postoperative subconjunctival 5-fluorouracil (5-FU) has considerably improved the success rate of glaucoma filtering surgery. However, because this antimetabolite may cause corneal epithelial defects in the early postoperative period and because of the inconvenience of repeated subconjunctival injections, the use of intraoperative sponge 5-FU has been proposed.6–10 Other antimetabolites have also been tried, including mitomycin C.11 Late bleb leakage, infection, and severe hypotony have been reported with this drug6 with documented irreversible maculopathy.12 This has led to re-evaluation of the use of 5-FU.

To assess the efficacy and safety of 5-FU applied at the time of trabeculectomy in Afro-Caribbean patients without other risk factors for failure, we analysed the results in 18 consecutive operations in which this technique was used. The surgical results were compared with those in a matched control group of 16 eyes who underwent trabeculectomy without 5-FU.

**Material and methods**

From 1992 to 1995, trabeculectomy was performed with adjunctive 5-FU application in 18 eyes of 18 consecutive Afro-Caribbean patients. Informed consent was obtained from all patients. A control group of 16 eyes of 16 Afro-Caribbean patients who had undergone trabeculectomy for glaucoma without antimetabolite therapy was identified retrospectively. Exclusion criteria for both groups were: traumatic glaucoma; patient age of 30 years or younger; previous surgery to the conjunctiva including trabeculectomy, aphakia, pseudophakia, uveitic glaucoma, previous argon laser trabeculoplasty in the past 6 months; and neovascular glaucoma.

In those patients receiving intraoperative 5-FU the conjunctival flap was limbus based in 16 cases and fornix based in two cases. In the control group the conjunctival flap was limbus based in 12 cases and fornix based in four cases. After haemostasis of the episclera was attained, 5-FU was applied between sclera and Tenon’s capsule for 5 minutes with a surgical sponge that measured approximately 4.5 × 4.5 mm and that had been previously soaked in a 25 mg/ml solution of 5-FU (David Bull Laboratories, Warwick).

After 5 minutes the sponge was removed and the entire area was thoroughly irrigated with 40 ml balanced saline solution. A 4.0 × 4.0 mm limbus based scleral flap was dissected into clear cornea. A 1.00 × 2.00 mm deep scleral block was removed and a peripheral iridectomy was performed. The scleral flap was closed by two interrupted 10-0 nylon sutures. Tenon’s capsule and the conjunctival layer were sutured by using a continuous 8-0 Vicryl suture on a round bodied needle for limbus based flaps. In patients where a fornix based conjunctival flap was used the conjunctiva was closed with interrupted 8-0 Vicryl sutures. Subconjunctival injection of 20 mg cefuroxime and 1.5 mg betamethasone acetate was administered in the inferior fornix. Postoperatively, topical chloramphenicol was used four times daily for 4 postoperative weeks and topical prednisolone 1% or dexamethasone 0.1% was used four to six times a day for 2 months and progressively tapered over an additional month.

Patients were examined 1, 7, and 15 days postoperatively and then 1, 3, 6, 9, 12, 15, 18, and 24 months postoperatively. At each postoperative visit patients were fully examined...
Table 1  Patient characteristics in two groups of patients who received trabeculectomy with or without intraoperative 5-FU

<table>
<thead>
<tr>
<th></th>
<th>Trabeculectomy with 5-FU (n=18)</th>
<th>Control group (n=16)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years): Mean (SD)</td>
<td>50.5 (16.1)</td>
<td>55.8 (15.1)</td>
<td>0.37</td>
</tr>
<tr>
<td>Range</td>
<td>30–70</td>
<td>38–68</td>
<td></td>
</tr>
<tr>
<td>Sex: Male</td>
<td>10 (55%)</td>
<td>10 (62%)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>8 (45%)</td>
<td>6 (38%)</td>
<td></td>
</tr>
<tr>
<td>Follow up (months): Mean</td>
<td>17.4 (4.8)</td>
<td>23.5 (1.6)</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>12–24</td>
<td>12–24</td>
<td></td>
</tr>
<tr>
<td>Preoperative IOP (mm Hg): Mean (SD)</td>
<td>24.9 (4.1)</td>
<td>24.0 (3.0)</td>
<td>0.56</td>
</tr>
<tr>
<td>Number of medications</td>
<td>1.57 (0.51)</td>
<td>1.82 (0.26)</td>
<td>0.2</td>
</tr>
<tr>
<td>Duration of medications</td>
<td>3.66 (3.05)</td>
<td>4.26 (3.52)</td>
<td>0.35</td>
</tr>
</tbody>
</table>

Results

Table 1 lists the patient characteristics, follow up, and preoperative intraocular pressures. The trial and control group were well matched with no statistical difference between the two groups for age, preoperative intraocular pressure, number of topical medications, and cumulative duration of medications used.

Table 2 lists the intraocular pressure outcome. The intraocular pressure reduction was greater in the 5-FU group at the first month but the difference was not statistically significant. Evolution of intraocular pressure in the two groups is presented in Figures 1, 2, and 3.

The Kaplan–Meier survival curve for trabeculectomy with intraoperative sponge 5-FU is shown in Figure 4. The difference, using the log rank test is not statistically significant.

The complications encountered in this series are listed in Table 3.

In the control group seven patients (43%) required additional medical therapy; four patients required one drug (β blocker), and three patients required two drugs (β blocker + pilocarpine). Four of these seven patients received two 5-FU injections (5 mg) at the end of the second month, as an attempted treatment for bleb failure. One patient had a second trabeculectomy with antimetabolite (mitomycin C) 8 months after the first trabeculectomy. These four patients were considered as early failures. In the 5-FU group two patients required a second trabeculectomy (with mitomycin C), the first one at 3 months and the second at 6 months after the initial trabeculectomy. Eight patients (44%) in total required additional therapy medical or surgical.

Discussion

Antimetabolites are used to reduce risk of surgical failure from postoperative scarring of the trabeculectomy bleb. Poor success rates after routine filtration operations in black patients have been reported suggesting the need for antimetabolites. The use of postoperative subconjunctival injection of 5-FU or intraoperative application of mitomycin C has considerably improved the success rate of the glaucoma filtering procedure. However, the use of a single 5 minute application of 5-FU during glaucoma filtration surgery has been proposed to avoid the serious complications seen with mitomycin and avoiding the need to administer repeated subconjunctival injections in accordance with the original protocols for the use of 5-FU.
It is interesting to note that the recently published 5 year follow up of the Filtering Surgery Study Group suggested that young age and Afro-Caribbean race were not significant additional risk factors for filtering surgery failure in their group of eyes considered at high risk for bleb failure—that is, aphakia, pseudophakia, and previous glaucoma surgery.17 Other studies have been published on the use on antimetabolites in filtering surgery.18 The main problem encountered in comparing previous studies using antimetabolites is the failure to standardise risk factors for failure (type of glaucoma, race, or previous surgery) making it difficult to isolate the effect of antimetabolite on success rate. The definition of success criteria is also variable depending on the level of IOP required and the use of postoperative medications.

Smith et al7 have shown the clinical efficacy of topical peroperative 5-FU (50 mg/ml) in 14 patients (seven during initial trabeculectomy and seven with complicated glaucoma) with a mean follow up of 6.4 months. However, although the 5-FU was applied intraoperatively additional subconjunctival 5-FU injections with an average of 5.8 injections (mean total dose 29 mg) were also given.

In a series of patients at risk of filtration failure, those that underwent trabeculectomy with a single intraoperative 5 minute exposure of sclera and subconjunctival tissues to 5-FU (25 mg/ml) showed good results but the follow up period was limited (3 to 9 months).4 Feldman et al19 reported a 6 month prospective series of 43 cases with intraoperative 5-FU including eight black patients. Seven patients were treated successfully but adjunctive medication treatment was permissible.

More recently, in a study of trabeculectomy with intraoperative sponge 5-FU,20 105 of 140 eyes required supplementary injections of 5-FU with a mean number of injections of 5.3 (SD 2.7) (range 1–14). For low risk eyes (eyes without risk factors except for previous topical medications) the mean number of injections was 4.0 (2.4), and for high risk eyes the mean number was 5.7 (3.2) injections.

A Ghanian series15 of 55 eyes with a mean follow up of 282 days randomly selected to receive or not receive a single application of 5-FU (50 mg/ml 5 minutes) without use of postoperative injections concluded that intraoperative 5-FU improved the ability of trabeculectomy to lower intraocular pressure in a black African population. The number of eyes with previous operations was not statistically different in the two groups but the use and the number of preoperative medications was not mentioned.

We used a concentration of 25 mg/ml of 5-FU based on laboratory studies.20 This is the highest concentration commercially available in the UK.

Laboratory studies suggest that a 5 minute 5-FU exposure should be effective in inhibiting the proliferation of ocular fibroblasts.20–23 In a masked randomised prospective study in a rabbit model21 a single intraoperative exposure to 5-FU (50 mg/ml concentration for 5 minutes) resulted in consistently higher blebs than a placebo (distilled water). However, in the same study it was shown that a combination of intraoperative and postoperative 5-FU (five injections on postoperative days 1, 3, 5, 7) produced significantly higher blebs than intraoperative 5-FU alone.

Khaw et al22 compared the effect of a single application of mitomycin (0.4 mg/ml) and 5-FU (50 mg/ml), demonstrating that 5 minute intraoperative treatments with 5-FU resulted in a reversible delay of fibroblast outgrowth from treated subconjunctival and scleral tissues of just over 1 week in an animal model (white albino rabbit), whereas treatment
with mitomycin C 0.4 mg/ml, resulted in prolonged inhibition for at least 30 days. The same authors also showed that in rabbits intraoperative sponge 5-FU significantly increases bleb survival, though not to the same extent as does mitomycin C. At 30 days after surgery, blebs were present in 100% of eyes treated with mitomycin C 0.4 mg/ml, 60% of eyes treated with 0.2 mg/ml, and 0% of eyes treated with distilled water or a single 5-minute application intraoperative exposure to 5-FU (50 mg/ml).

In our study no major complications were noted. Sponge application of 5-FU did not appear to cause corneal epithelial toxicity. However, we were not able to demonstrate that a single intraoperative application of 5-FU enhanced the success rate of trabeculectomy in the Afro-Caribbean population. Our success rate is lower than in primary trabeculectomy without antimetabolite but comparable with other studies of black populations (Table 4).

Conclusion

Although this study reported two groups with a small number of patients our results suggest that in Afro-Caribbean patients the success rate of trabeculectomy is not enhanced by a single intraoperative application of 5-FU. It may be that additional postoperative 5-FU injections are required to achieve satisfactory results in this group of patients. A prospective study comparing intraoperative sponge 5-FU combined with additional postoperative subconjunctival injections with intraoperative mitomycin C would be helpful to assess the role of a higher level of antifibrosis suppression in this group of patients.

The authors have no proprietary interest in any of the materials used in this study.


Table 4  Previously success rates of trabeculectomy surgery in Afro-Caribbean patients

<table>
<thead>
<tr>
<th>Authors</th>
<th>N</th>
<th>Antimetabolite</th>
<th>Follow up</th>
<th>Success criteria</th>
<th>% Success</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Freedman et al.</td>
<td>51</td>
<td>No</td>
<td>19 months</td>
<td>IOP &lt;20 without meds</td>
<td>57</td>
<td></td>
</tr>
<tr>
<td>David et al.</td>
<td>19</td>
<td>No</td>
<td>6-30 months</td>
<td>IOP &lt;20 with or without meds</td>
<td>73.6</td>
<td></td>
</tr>
<tr>
<td>Thommy et al.</td>
<td>139</td>
<td>No</td>
<td>6 months</td>
<td>IOP &lt;20 without meds</td>
<td>95</td>
<td></td>
</tr>
<tr>
<td>Wilson et al.</td>
<td>32</td>
<td>No</td>
<td>9 months</td>
<td>IOP &lt;20 without meds</td>
<td>53</td>
<td></td>
</tr>
<tr>
<td>Mermoud et al.</td>
<td>30</td>
<td>Mitomycin (0.2 mg/ml)</td>
<td>9 months</td>
<td>IOP &lt;20 without meds</td>
<td>83</td>
<td></td>
</tr>
<tr>
<td>Egbert et al.</td>
<td>31</td>
<td>No</td>
<td>5-FU (50 mg/ml)</td>
<td>28 days</td>
<td>32</td>
<td></td>
</tr>
<tr>
<td>Current study</td>
<td>16</td>
<td>5-FU</td>
<td>18 months</td>
<td>IOP &lt;22 without meds</td>
<td>55</td>
<td></td>
</tr>
<tr>
<td></td>
<td>18</td>
<td>5-FU (25 mg/ml)</td>
<td>18 months</td>
<td>IOP &lt;22 without meds</td>
<td>56</td>
<td></td>
</tr>
</tbody>
</table>

N= number of eyes.


